
Former Roche CEO joins Arix Bioscience as senior independent director
pharmafile | November 10, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
Arix Bioscience, a Britain-based healthcare and life science company, appointed Franz Humer as a senior independent director on 31 October. Franz Humer arrives with a wealth of industry experience after having worked as chief executive officer and chairman of Roche for 16 years. He is currently a chairman of Biageo and a non-exeuctive director of Citigroup, Kite Pharma and Chugai Pharmaceutical.
Jonathan Peacock, chairman of Arix Bioscience, said: “We are delighted to welcome to the board a director of Franz’s stature. His experience and judgement will be a tremendous asset to Arix Bioscience as we continue to support emerging and innovative companies globally. Franz further strengthens a very experience board of executive and non-executive directors.”
Franz Humer said: “Arix Bioscience offers a much needed new approach to supporting innovation in our industry. Its team has outstanding breadth of expertise in nurturing promising start ups, broad operating skills and a strong track record in creating and developing successful companies in the healthcare and life science sector with scope to offer significant patient benefit. I look forward to working with the Board and supporting the executive team in building the Arix business and helping to realise substantial value for shareholders.”






